Gilead Sciences has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its Trodelvy (sacituzumab govitecan) to treat breast cancer.

Trodelvy will be used as a monotherapy to treat unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (not containing high levels of the protein HER-2) breast cancer in patients who have previously received endocrine-based therapy and a minimum of two additional systemic therapies in the advanced setting.

The European Commission’s final decision on the additional indication is expected later this year.

Trodelvy is a first-in-class Trop-2 directed antibody-drug conjugate designed with a proprietary hydrolyzable linker that is attached to SN-38, a topoisomerase I inhibitor payload.

Gilead oncology therapeutic area head and senior vice-president Bill Grossman stated: “When patients with HR+/HER2- metastatic breast cancer develop resistance to endocrine-based therapies, treatment options are limited.

“Trodelvy has the potential to change this outlook, and we aim to build on the demonstrated benefits in second-line metastatic triple-negative breast cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This positive recommendation from the CHMP marks another important step toward making a difference for patients with pre-treated HR+/HER2- metastatic breast cancer in Europe.”

The CHMP’s opinion was supported by the findings obtained from the Phase III TROPiCS-02 trial.

The open-label, multicentre, international Phase III trial was designed to assess Trodelvy against physicians’ choice of chemotherapy (eribulin, capecitabine, gemcitabine or vinorelbine) in 543 HR+/HER2- metastatic breast cancer patients who have previously received endocrine therapy, CDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease.

Trodelvy showed a statistically significant and clinically meaningful overall survival (OS) benefit of 3.2 months compared with single-agent chemotherapy.